HOME >> BIOLOGY >> NEWS
FUZEON with investigational HIV drug results in remarkable number of patients achieving undetectable

Basel, October 5, 2006 -- Exciting new clinical data demonstrate that 90 to 95 percent of treatment-experienced HIV patients who initiate therapy with FUZEON (enfuvirtide) and the investigational integrase inhibitor MK-0518 can achieve undetectable levels of HIV (less than 400 copies per mL of blood)1. Such response rates have never been achieved in clinical trials of HIV patients living with drug-resistant virus. This significant antiviral effect achieved by adding FUZEON to other new drugs, known as the "FUZEON effect", has been consistently demonstrated across a number of studies.2 These data were presented at the 46th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).

"These remarkable results show us that by partnering FUZEON and a novel integrase inhibitor, treatment-experienced patients can have a similar chance to achieve the ultimate goal of treatment, undetectable viral load, as treatment-nave patients," said Dr Anton Pozniak, the Chelsea and Westminster Hospital, London. "Today, we already see that using FUZEON with darunavir or tipranavir, we have the right drugs to help us achieve the treatment goal of undetectable viral load in the majority of treatment-experienced patients. But more importantly we look set to achieve this goal of undetectable in more patients in the future with the availability of FUZEON and exciting novel agents such as MK-0518."

About the results presented at ICAAC

Investigators reported results of a 24-week, Phase II, Merck-sponsored study of MK-0518 in treatment-experienced patients with resistance to protease inhibitors, nucleoside analogues and non-nucleoside analogues. Patients received one of three doses of MK-0518 (200 mg, 400 mg or 600 mg) twice-daily in combination with an optimised background regimen of anti-HIV drugs. In the subset of patients who received FUZEON for the first time in their drug regimen, 90 to 95 percent of 32 subjects achieved undetec
'"/>

Contact: Alexander Watson
alexander.watson@ketchum.com
44-771-267-5990
Ketchum
5-Oct-2006


Page: 1 2

Related biology news :

1. Providence health system shows investigational osteoporosis therapy increases bone mineral density
2. Sitagliptin, a new investigational treatment for type 2 diabetes, may offer new hope for patients
3. Amgen investigational therapy, AMG 162, increased bone mineral density with twice yearly injection
4. Cooperative science program yields results
5. Delayed treatment of childhood-onset bipolar disorder results in negative outcome in adults
6. Smelling for first time results from knowing abnormalities in congenital loss of smell
7. BDSI announces positive phase III clinical trial results
8. Scientists meet to review Envisat results after 5 years of operations
9. Environment and exercise may affect research results, UA study shows
10. Preliminary results of largest scan of autism DNA information
11. Human trial results show excellent safety data, from Geovaxs DNA/MVA AIDS vaccines

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... ... pharmaceuticals targeting mitochondria, in partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing ... Phase 3 VISTA-2 study of SkQ1 ophthalmic solution in patients with moderate ...
(Date:8/26/2020)... ... 2020 , ... Modality Solutions, a biopharmaceutical cold chain validation engineering ... The list is the most prestigious ranking of the nation’s fastest-growing private companies. Modality ... list, reported three-year revenue growth of 71 percent. , The Inc. 5000 list ...
(Date:8/21/2020)... ... August 18, 2020 , ... Sentien Biotechnologies, Inc., a ... U.S. Food and Drug Administration (FDA) has approved the company’s Investigational New Drug ... of severe COVID-19. Approval of this IND allows Sentien to initiate a Phase ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 30, 2020 , ... ... sciences industry, today announced the release of its signature product called Beacon ... Liaisons (MSLs) and other field medical professionals. , Beacon helps MSLs ...
(Date:7/18/2020)... ... July 17, 2020 , ... dicentra ... life sciences and food industries, is pleased to announce that Charles Galea has ... Business Development. , Charles is an accomplished and results-driven sales executive with over ...
(Date:7/7/2020)... ... , ... R3 International is now offering stem cell therapy for Alzheimers dementia ... on the patient's condition, treatment may be offered IV, intrathecal or with a combination. ... Alzheimers dementia, and the incidence continues to increase as individuals live longer. There is ...
(Date:6/28/2020)... ... June 25, 2020 , ... The Indoor Lab, a ... Safe Space™ for businesses of all types to ensure cleanliness, distancing and occupancy with ... , A Safe Space™ enabled business will provide a health performance index system that ...
Breaking Biology Technology:
Cached News: